[go: up one dir, main page]

MX2019014331A - Polipeptidos que antagonizan la se?alizacion wnt en celulas tumorales. - Google Patents

Polipeptidos que antagonizan la se?alizacion wnt en celulas tumorales.

Info

Publication number
MX2019014331A
MX2019014331A MX2019014331A MX2019014331A MX2019014331A MX 2019014331 A MX2019014331 A MX 2019014331A MX 2019014331 A MX2019014331 A MX 2019014331A MX 2019014331 A MX2019014331 A MX 2019014331A MX 2019014331 A MX2019014331 A MX 2019014331A
Authority
MX
Mexico
Prior art keywords
wnt signaling
polypeptides
tumor cells
methods
lrp5
Prior art date
Application number
MX2019014331A
Other languages
English (en)
Inventor
Staelens Stephanie
Cromie Karen
ZINZALLA Vittoria
Strubbe Beatrijs
Kuenkele Klaus-Peter
Buyse Marie-Ange
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59021278&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019014331(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2019014331A publication Critical patent/MX2019014331A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/04—Dimeric indole alkaloids, e.g. vincaleucoblastine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La invención proporciona polipéptidos de fijación a LRP5 novedosos y, más específicamente, constructos de dominio variable único de inmunoglobulina de fijación a LRP5 novedosos, que pueden inhibir las vías de señalización Wnt. La invención también se refiere a secuencias específicas de estos polipéptidos, métodos para su producción y métodos para usarlos, que incluyen métodos para el tratamiento de enfermedades, tales como cáncer.
MX2019014331A 2017-05-31 2018-05-30 Polipeptidos que antagonizan la se?alizacion wnt en celulas tumorales. MX2019014331A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17173782 2017-05-31
PCT/EP2018/064295 WO2018220080A1 (en) 2017-05-31 2018-05-30 Polypeptides antagonizing wnt signaling in tumor cells

Publications (1)

Publication Number Publication Date
MX2019014331A true MX2019014331A (es) 2020-01-27

Family

ID=59021278

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014331A MX2019014331A (es) 2017-05-31 2018-05-30 Polipeptidos que antagonizan la se?alizacion wnt en celulas tumorales.

Country Status (25)

Country Link
US (3) US11033636B2 (es)
EP (1) EP3630816B1 (es)
JP (1) JP7216024B2 (es)
KR (1) KR102717656B1 (es)
CN (1) CN110637030B (es)
AR (1) AR111840A1 (es)
AU (1) AU2018276409B2 (es)
BR (1) BR112019022729A2 (es)
CA (1) CA3060401A1 (es)
CL (1) CL2019003419A1 (es)
CO (1) CO2019012329A2 (es)
EA (1) EA201992808A1 (es)
ES (1) ES2979194T3 (es)
HU (1) HUE067691T2 (es)
IL (1) IL270854B2 (es)
MA (1) MA48760A (es)
MX (1) MX2019014331A (es)
MY (1) MY200744A (es)
PE (1) PE20200610A1 (es)
PH (1) PH12019502602A1 (es)
PL (1) PL3630816T3 (es)
TW (1) TWI887192B (es)
UA (1) UA125761C2 (es)
WO (1) WO2018220080A1 (es)
ZA (1) ZA201906610B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019014331A (es) * 2017-05-31 2020-01-27 Boehringer Ingelheim Int Polipeptidos que antagonizan la se?alizacion wnt en celulas tumorales.
KR102776166B1 (ko) 2017-08-07 2025-03-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 안전한 세포 치료제를 생성하기 위한 플랫폼
EP4603508A3 (en) 2017-12-19 2025-10-29 Surrozen Operating, Inc. Anti-frizzled antibodies and methods of use
CA3085785A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Anti-lrp5/6 antibodies and methods of use
CA3085782A1 (en) 2017-12-19 2019-06-27 Surrozen, Inc. Wnt surrogate molecules and uses thereof
WO2020080941A1 (en) * 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
AU2020221797A1 (en) * 2019-02-11 2021-08-12 Surrozen Operating, Inc. Modulation of WNT signalling in ocular disorders
JP2022526166A (ja) * 2019-03-29 2022-05-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗癌併用療法
WO2021026665A1 (en) * 2019-08-14 2021-02-18 Modmab Therapeutics Inc. Antibodies that bind to lrp5 proteins and methods of use
WO2023250402A2 (en) * 2022-06-22 2023-12-28 Antlera Therapeutics Inc. Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof
WO2023243759A1 (ko) * 2021-07-13 2023-12-21 인제대학교 산학협력단 Neurl 유전자, 이를 포함하는 발현벡터 또는 neurl 단백질을 유효성분으로 포함하는 β-카테닌 과발현으로 인한 암질환 예방 또는 치료용 약학조성물
JP2024530656A (ja) * 2021-08-10 2024-08-23 ヒート バイオロジクス，インコーポレイテッド． 新規Ｔｉｍ－４結合剤の作製及び特性決定
CN114702588B (zh) * 2022-04-27 2022-11-22 博际生物医药科技(杭州)有限公司 抗Nectin-4抗体和双特异性抗体

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE420178T1 (de) 1992-08-21 2009-01-15 Univ Bruxelles Immunoglobuline ohne leichtkette
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
ES2285767T3 (es) 1997-04-15 2007-11-16 MERCK & CO., INC. Receptor de ldl.
US6329516B1 (en) 1997-04-28 2001-12-11 Fmc Corporation Lepidopteran GABA-gated chloride channels
WO2001077137A1 (en) 2000-04-12 2001-10-18 Human Genome Sciences, Inc. Albumin fusion proteins
BR0209836A (pt) 2001-05-17 2004-12-07 Genome Therapeutics Corp Método para regular a atividade de lrp5, lrp6 ou hbm em um paciente, e do caminho dkk-wnt em um paciente, para modular a massa óssea e os nìveis de lipìdeo em um paciente, para diagnosticar a massa óssea alta ou baixa e/ou os nìveis de lipìdeos altos ou baixos em um paciente, para triar um composto que modula a interação de dkk com lrp5, lrp6, hbm ou um fragmento de ligação de dkk de lrp5, lrp6 ou hbm, e de dkk com uma proteìna que interage com a dkk, composição, composição farmacêutica, métodos para identificar compostos que modulem as interações da dkk e lrp5/lrp6/hbm, e para identificar parceiros de ligação para uma proteìna de dkk, ácido nucléico que codifica um aptâmero peptìdico da proteìna que interage com dkk, vetor, método para detectar uma atividade moduladora de um composto, animal transgênico, método para identificar compostos potenciais que modulem a atividade da dkk, aptâmero peptìdico, anticorpo ou fragmento de anticorpo, e, métodos para identificar proteìnas que interagem com a dkk modulando a interação da dkk com o caminho de sinalização wnt, para identificar compostos que modulem a interação da dkk com o caminho de sinalização wnt, para testar compostos que modulam a atividade mediada pela dkk em um mamìfero, e para triar compostos ou composições que modulam a interação da dkk e uma proteìna que interage com a dkk
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
CA2484556A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
EP1600459A3 (en) * 2002-06-28 2005-12-07 Domantis Limited Ligand
AU2003286004A1 (en) 2002-11-08 2004-06-07 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
BRPI0518151A2 (pt) 2004-10-13 2009-06-16 Ablynx Nv polipetìdeos contra amiloide-beta, ácido nucléico que codifica tal polipetìdeo, composição compreendendo tal polipetìdeo, método para produzir um polipetìdeo e uso do mesmo
EP3613767A1 (en) 2005-05-18 2020-02-26 Ablynx N.V. Improved nanobodiestm against tumor cecrosis factor-alpha
WO2007027509A2 (en) * 2005-08-31 2007-03-08 Biogen Idec Ma Inc. Evaluating and treating scleroderma
JP2010500876A (ja) 2006-08-18 2010-01-14 アブリンクス エン．ヴェー． Ｉｌ−６媒介性シグナル伝達に関連する疾患及び障害の治療のための、ｉｌ−６ｒに指向性を有するアミノ酸配列及びこれを含むポリペプチド
US20100113339A1 (en) 2006-09-08 2010-05-06 Ablynx N. V. Serum albumin binding proteins with long half-lives
JP2010511397A (ja) 2006-12-05 2010-04-15 アブリンクス エン．ヴェー． 血清タンパク質と結合可能なペプチド
CA2717015A1 (en) 2008-03-05 2009-09-11 Ablynx Nv Novel antigen binding dimer-complexes, methods of making and uses thereof
EP2268668A1 (en) 2008-04-17 2011-01-05 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
US8716243B2 (en) 2008-05-28 2014-05-06 St. Jude Childen's Research Hospital Methods of effecting Wnt signaling through Dkk structural analysis
CA2777527C (en) 2009-12-23 2020-06-23 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
AU2011212442A1 (en) 2010-02-05 2012-08-09 Ablynx Nv Peptides capable of binding to serum albumin and compounds, constructs and polypeptides comprising the same
CA2788275A1 (en) 2010-03-03 2011-09-09 Boehringer Ingelheim International Gmbh Biparatopic abeta binding polypeptides
EP2550295A1 (en) * 2010-03-24 2013-01-30 F. Hoffmann-La Roche AG Anti-lrp6 antibodies
CA2798390A1 (en) 2010-05-06 2011-11-10 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies
EP2566892B1 (en) 2010-05-06 2017-12-20 Novartis AG Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
CN103501799A (zh) * 2011-01-28 2014-01-08 莱兰斯坦福初级大学评议会 Wnt组合物及其使用方法
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
US8790650B2 (en) 2011-04-28 2014-07-29 Vanderbilt University Methods of using an antibody to inhibit WNT-mediated cardiac remodeling
SG10201605048XA (en) 2011-06-23 2016-07-28 Ablynx Nv Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
TW201321405A (zh) 2011-08-17 2013-06-01 Glaxo Group Ltd 經修飾之蛋白質及肽
EP3252075A1 (en) 2011-11-04 2017-12-06 Novartis AG Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
EP2804629A1 (en) 2012-01-18 2014-11-26 Genentech, Inc. Anti-lrp5 antibodies and methods of use
JP7046804B2 (ja) * 2015-11-18 2022-04-04 アブリンクス エン．ヴェー． 改良された血清アルブミン結合剤
US10597449B2 (en) * 2015-12-04 2020-03-24 Boehringer Ingelheim International Gmbh Biparatopic polypeptides antagonizing Wnt signaling in tumor cells
MX2019014331A (es) * 2017-05-31 2020-01-27 Boehringer Ingelheim Int Polipeptidos que antagonizan la se?alizacion wnt en celulas tumorales.
JP2022526166A (ja) * 2019-03-29 2022-05-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗癌併用療法

Also Published As

Publication number Publication date
JP2020521478A (ja) 2020-07-27
IL270854B (en) 2022-10-01
WO2018220080A1 (en) 2018-12-06
AU2018276409A1 (en) 2019-10-31
KR20200011933A (ko) 2020-02-04
EP3630816B1 (en) 2024-03-20
BR112019022729A2 (pt) 2020-05-19
PL3630816T3 (pl) 2024-08-05
US11033636B2 (en) 2021-06-15
UA125761C2 (uk) 2022-06-01
HUE067691T2 (hu) 2024-11-28
US12285493B2 (en) 2025-04-29
TW201906858A (zh) 2019-02-16
IL270854B2 (en) 2023-02-01
IL270854A (en) 2020-01-30
CL2019003419A1 (es) 2020-03-27
CA3060401A1 (en) 2018-12-06
TWI887192B (zh) 2025-06-21
EA201992808A1 (ru) 2020-05-14
MA48760A (fr) 2020-04-08
US20220362393A1 (en) 2022-11-17
US20180344868A1 (en) 2018-12-06
CN110637030B (zh) 2024-06-11
EP3630816C0 (en) 2024-03-20
EP3630816A1 (en) 2020-04-08
PE20200610A1 (es) 2020-03-10
PH12019502602A1 (en) 2020-06-08
US20250345448A1 (en) 2025-11-13
ES2979194T3 (es) 2024-09-24
AR111840A1 (es) 2019-08-21
MY200744A (en) 2024-01-13
KR102717656B1 (ko) 2024-10-14
ZA201906610B (en) 2025-12-17
AU2018276409B2 (en) 2025-02-27
JP7216024B2 (ja) 2023-01-31
CO2019012329A2 (es) 2020-01-17
CN110637030A (zh) 2019-12-31

Similar Documents

Publication Publication Date Title
PH12019502602A1 (en) Polypeptides antagonizing wnt signaling in tumor cells
SA518391728B1 (ar) بولي بيبتيدات ثنائية المستوقع المضادة لإشارة ونت في خلايا ورم
PH12020552080A1 (en) Dll3-cd3 bispecific antibodies
ZA202303412B (en) Anti-galectin-9 antibodies and uses thereof
PH12019501959A1 (en) Therapeutic rna
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
PH12019501357A1 (en) Anti-ox40 antibodies and their uses
MX2018006973A (es) Anticuerpos anti-cd73 humanizados.
PH12017501483A1 (en) Bicyclic heterocycles as fgfr4 inhibitors
HK1245080A1 (zh) 自然杀伤细胞的方法和组合物
MX2023004221A (es) Inhibidores de rad51.
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
BR112017024384A2 (pt) bactérias modificadas para reduzir hiperfenilalaninemia
EA202090516A3 (ru) Бициклические гетероциклы в качестве ингибиторов fgfr
MX2017004715A (es) Anticuerpos anti-ox40 humanizados y usos de los mismos.
MX374463B (es) Anticuerpos anti-egfr y usos de los mismos.
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
NZ746609A (en) Ilt7 binding molecules and methods of using the same
MY194041A (en) Anti-tnfalpha-antibodies and functional fragments thereof
MX2020000636A (es) Proteinas sinteticas y usos terapeuticos de las mismas.
PH12021551419A1 (en) New conjugated nucleic acid molecules and their uses
MX2020006641A (es) Proceso para la preparacion de compuestos de pirimidinil-4-aminopi razol.
EA201650085A1 (ru) Способ лечения опухолевого заболевания и способ селективного ингибирования роста опухолевых клеток с помощью производного хиноксалин-1,4-диоксида